Shilpa Medicare Limited (NSE:SHILPAMED)

Market Cap	185.11B +157.6%
Revenue (ttm)	18.44B +37.3%
Net Income	3.32B +142.2%
EPS	13.60 +93.9%
Shares Out	n/a
PE Ratio	69.55
Forward PE	48.78
Dividend	0.60 (0.06%)
Ex-Dividend Date	Sep 4, 2026

Volume	297,595
Open	940.00
Previous Close	933.85
Day's Range	936.00 - 955.00
52-Week Range	259.50 - 1,095.00
Beta	0.37
Analysts	Buy
Price Target	981.50 (+3.77%)
Earnings Date	Nov 5, 2026

About Shilpa Medicare

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 1,241
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SHILPAMED

Financial Performance

In fiscal year 2026, Shilpa Medicare's revenue was 15.40 billion, an increase of 19.60% compared to the previous year's 12.88 billion. Earnings were 2.43 billion, an increase of 210.81%.

Analyst Summary

According to 4 analysts, the average rating for SHILPAMED stock is "Buy." The 12-month stock price target is ₹981.50, which is an increase of 3.77% from the latest price.

Price Target

₹981.50

(3.77% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error